Enliven Therapeutics, Inc. (NasdaqGS: ELVN)
Health Care · Pharmaceuticals · US
$59.08
-1.24% today · +186.9% 1Y
Enliven Therapeutics, Inc. (NasdaqGS: ELVN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.38B and employs 61 people.
Over the last twelve months the share price has gained 186.9%, trading between 14.79 and 62.32.
Tweenvest scores Enliven Therapeutics, Inc. across four factors: quality 29/100. Its strongest factor is quality.
ELVN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.38B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.67
- Dividend yield
- —
- Beta (5Y)
- 0.24
- 52-week high
- $62.32
- 52-week low
- $14.79
- Avg volume (3M)
- —
- Shares outstanding
- 73.27M
- Employees
- 61
- Next earnings
- —
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
- Founded
- 2019
- Listed since
- Mar 12, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.11 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.93 | +0.63% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.78 | +0.15% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.